Figure 1.

Dose-dependent inhibition of proliferation in prostate cancer cell lines by sorafenib. LNCaP, 22Rv1, PC3, and LNCaP-IL6+ cells were exposed to increasing concentrations of sorafenib in HITES medium for 48 h. (A) Proliferation was assessed by ³H-thymidine incorporation. (B) Protein expression of CDK2 and cyclin D1 was detected by western blotting. Bands were scanned densitometrically and normalized to expression levels of GAPDH. Representative western blots from at least three independent experiments are shown. (A and B) Statistical significances are calculated against the DMSO-treated cells and values indicated are mean±s.e.m., n≥3. */# P<0.05; **/## P<0.01; ***/### P<0.001. POI, protein of interest.